Preliminary programme

Extended info:

Sun 19 Oct 2025

17:00 - 20:00

Poster mounting REG02

Poster Halls

Registration desk open REG01

Registration desk

Mon 20 Oct 2025

09:00 - 18:00

Registration desk open REG03

Registration desk

10:00 - 11:00

PLE

Plenary opening and keynotes PLE01

Auditorium 1 - Plenary Hall

Chairs

Colin RUSSELL

ESWI Board Member, Academic Medical Center, University of Amsterdam, Netherlands

Ab OSTERHAUS

ESWI Board Member, TiHO, Germany

Stefania MAGGI

ESWI Board Member, National Research Council of Italy, Italy

Marco GOEIJENBIER

ESWI Board Member, Spaarne Gasthuis, Netherlands

11:00 - 11:30

Coffee Break COF01

Exhibition hall

Poster mounting REG04

Poster Halls

11:30 - 13:00

SCS

Innate and adaptive immunity SCS01

Auditorium 1 - Plenary Hall

Chairs

Guus RIMMELZWAAN

University of Veterinary Medicine, Hannover, Germany

Kevin SELVA

Doherty Institute, University of Melbourne, Australia

Increasing SARS-CoV-2 IgG4 following repeated mRNA boosters negatively impact antibody functions across Omicron variants and sarbecoviruses

Kevin SELVADoherty Institute, University of Melbourne, Australia
Impact of Aging on CD8+ T Cell Immunity to Circulating and Pandemic Viruses

Carolien VAN DE SANDTESWI Associate Member, The University of Melbourne at the Doherty Institute, Australia
Detection of pre-existing humoral immunity against influenza virus H5N1 clade 2.3.4.4b in unexposed individuals

Christoph KREERUniversity of Cologne, Germany
SYSTEMIC AND MUCOSAL ANTIBODY SIGNATURES OF PROTECTION AGAINST SARS-COV-2 TRANSMISSION

To be confirmed
Obesity modulates tracheal and cardiac responses to influenza A virus infection

Betina Lyngfeldt HENRIKSENTechnical University of Denmark, Denmark
Prior influenza vaccination shapes subsequent vaccine responses in a randomized placebo-controlled trial

To be confirmed

SCS

Pandemic Preparedness SCS02

Auditorium 2 - Breakout

Chair

Ab OSTERHAUS

ESWI Board Member, TiHO, Germany

Observed Immunogenicity After Two Doses of an MF59-Adjuvanted Cell Culture–Derived H5N8 Influenza Vaccine (aH5N8c) in Healthy Subjects Aged ≥18 Years

To be confirmed
Immunogenicity of Homologous or Heterologous Booster Vaccinations with MF59-Adjuvanted, Cell Culture–Derived H5N8 or H5N6 Influenza Vaccines in Healthy Subjects Aged ≥18 Years

To be confirmed
When can sequence data confirm transmission links in respiratory virus outbreaks?

To be confirmed
Broad-Spectrum Baseline Immunity Against Highly Pathogenic Avian Influenza A(H5N1) Clade 2.3.4.4b Viruses in Dutch Healthcare Workers: Insights into Both Humoral and Cellular Immune Responses

Willemijn RIJNINKErasmus MC, Netherlands
Evaluating Cross-Protective Antibody Responses to Influenza A(H5N8) Vaccine in High-Risk Groups

Oona LIEDESFinnish Institute for Health and Welfare, Finland
OVX836, a Nucleoprotein based vaccine under clinical development, offers protection against Highly Pathogenic Avian Influenza viruses (H5N1 and H7N9) in mouse and ferret models

Florence NICOLASOsivax, France

SPI

ESWI invites coalition partners: Life Course Immunisation: A Seamless Approach to Protection Across All Ages SPI01

Auditorium 3 - Breakout

Chairs

Stefania MAGGI

ESWI Board Member, National Research Council of Italy, Italy

Catherine WEIL OLIVIER

independent expert, Trustee of CLCI, France

Understanding life course immunisation

Stefania MAGGIESWI Board Member, National Research Council of Italy, Italy

Catherine WEIL OLIVIERindependent expert, Trustee of CLCI, France
Age-specific immunisation needs and challenges

Paula TÄHTINENESWI Board Member, Turku University Hospital and University of Turku, Finland

Nicola VERONESEUnicamillus University, Italy
Burden of disease

Catherine MOOREPublic Health Wales, UK
Nurses and Pharmacists as Immunisation Champions

Ber OOMENESNO, Netherlands

13:00 - 14:30

Lunch LUN01

Exhibition hall

Poster mounting REG05

Poster Halls

13:15 - 14:15

SAT

Satellite Symposium organised by AstraZeneca: Unfolding the story of the immune response to intranasal live attenuated influenza vaccines SAT01

Auditorium 2 - Breakout

14:30 - 16:00

SCS

Future vaccination strategies - PART 1 SCS03

Auditorium 1 - Plenary Hall

Chairs

Florian KRAMMER

ESWI Board Member, Medical University of Vienna, Austria

Marios KOUTSAKOS

University of Melbourne, Australia

A Dendritic Cell-targeting Approach to Deliver a Universal Influenza Vaccine Candidate to the Respiratory Mucosa

Daryl LEENational University of Singapore, Singapore
Development of a next-generation COVID-19 intranasal vaccine based on a multivalent NDV-HXP-S formulation.

Marta BOZA CUENCAIcahn School of Medicine at Mount Sinai, United States
Superior protection and prevention of transmission upon influenza infection by adjuvanted mucosal vaccination in the guinea pig influenza model.

To be confirmed
Broad betacoronavirus immunity and SARS-CoV-2 protection induced by divergent spike-based nucleoside-modified vaccines

Anass ABBADIcahn Medical School at Mount Sinai, United States
The Additive Effect of Neuraminidase Inclusion in Influenza Vaccine Formulations using a Self-Amplifying RNA Platform

Giuseppe PALLADINOCSL, United States
Evaluation of a broadly protective influenza B virus vaccine based on mosaic hemagglutinin platforms in mice.

Irene GONZÁLEZ-DOMÍNGUEZIcahn School of Medicine at Mount Sinai, United States

SCS

Virus and host factors in pathogenesis SCS04

Auditorium 2 - Breakout

Chairs

Debby VAN RIEL

ESWI Associate Member, Erasmus MC, Netherlands

Anders MADSEN

Haukeland University Hospital, Norway

Avian influenza viruses re-shape the hormonal landscape by inducing pulmonary CYP19A1 expression in golden hamsters

Sebastian BECKLeibniz Institute of Virology, Germany
Obesity increases the risk for severe COVID 19 – An obese hamster model to study sex-specific differences in the underlying pathophysiology

Zoé SCHMALLeibniz Institute of Virology, Germany
Inter-strain differences in influenza-host interactions in recent seasonal human influenza strains

To be confirmed
Functional Balance of HA and NA in Emerging Porcine Influenza A Viruses: Sialoreceptor Dynamics at the Mucosal Interface

Mengying LIUUtrecht University, Netherlands
Cell Tropism, Replication Dynamics, and effect on neural network activity to Seasonal and Pandemic Influenza A Virus Infection in a hiPSC-Derived Neural Co-Culture Model

Feline BENAVIDESErasmus MC, Netherlands
Single-cell profiling of inflammatory lung injury in clade 2.3.4.4b H5N1 influenza infected mice

Ying LIUThe University of Hong Kong, Hong Kong SAR China

SPI

Burden of disease in acute respiratory virus infections SPI02

Auditorium 3 - Breakout

Chairs

Paula TÄHTINEN

ESWI Board Member, Turku University Hospital and University of Turku, Finland

Stefania MAGGI

ESWI Board Member, National Research Council of Italy, Italy

Risk factors associated with severe health outcomes among older adults hospitalized with respiratory syncytial virus (RSV): understanding the pre-vaccine era landscape

Vajini ATUKORALEUniversity of Toronto, Canada

16:00 - 16:30

Coffee Break COF02

Exhibition hall

Poster mounting REG06

Poster Halls

16:30 - 17:30

SCS

Molecular virology SCS16

Auditorium 1 - Plenary Hall

Chair

Corine GEURTS VAN KESSEL

Erasmus MC, Netherlands

SAT

Satellite Symposium organised by Pfizer: RSV Vaccination in Adults: Integrating Current Clinical Trial Data and Real-World Insights SAT03

Auditorium 2 - Breakout

SAT

Satellite Symposium organised by ISRV: ISRV 20th Anniversary Lecture: Use of antivirals in pandemics: what have we learnt? SAT04

Auditorium 3 - Breakout

17:30 - 19:00

Welcome Refreshments and networking DIN01

Exhibition hall

19:00 - 20:00

ECAS

Early Career Scientists workshop - Communicating science - invitation only ECAS01

External

Tue 21 Oct 2025

08:15 - 09:15

SAT

Satellite Symposium: : A Shot in the Arm: Leveraging Combination Vaccines for Global Health Impact (a PeerVoice symposium supported by an educational grant from Moderna) SAT05

Auditorium 2 - Breakout

09:30 - 10:30

PLE

Science, Public Health, and Funding in a changing world PLE02

Auditorium 1 - Plenary Hall

10:30 - 11:00

Coffee Break COF03

Exhibition hall

11:00 - 12:30

SCS

Epidemiology and surveillance SCS05

Auditorium 1 - Plenary Hall

Chairs

Monika REDLBERGER-FRITZ

Medical University Vienna, Austria

Marco DEL RICCIO

University of Florence, Italy

Age at First Influenza A Virus Infection in Children and Impact of Influenza Vaccination

Kayla HANSONUniversity of Michigan School of Public Health, United States
Association of influenza viral genetic information with disease severity markers in hospitalized patients

Aung Pone MYINTUCBL1, France
Population-based Surveillance shows Burden of Hospitalisations and Severe Disease due to hMPV, RSV, and Influenza in Older Adults

To be confirmed
Impact of COVID-19 non-pharmaceutical interventions on antibody waning and the resurgence of human respiratory syncytial virus, seasonal coronavirus and influenza virus in a prospective cohort in The Netherlands

Channah GAASBEEKRIVM, Netherlands
Epidemiology of hospitalizations in older adults with lab-confirmed hMPV infection: A 14-year time series

To be confirmed
Epidemiology of human coronaviruses and impact of SARS-CoV-2 vaccination in paediatric patients in Hong Kong

Zirui GUOThe University of Hong Kong, Hong Kong SAR China

SCS

Virus Structure and replication SCS06

Auditorium 2 - Breakout

Chairs

Ed HUTCHINSON

ESWI Board Member, University of Glasgow

Lisa BAUER

Erasmus MC, Netherlands

Proteomic analysis of the subcellular reorganization during Influenza A infection in human cells

Laura GADEA-SALOMBIOTECMED, Universitat de València, Spain
Influenza NS1-Mediated N(6)-Methyladenosine Modification Controls NS mRNA Splicing

Yingyin LIAOThe University of Hong Kong, Hong Kong SAR China
Reassortment dynamics between clade 2.3.2.1 and 2.3.4.4b A(H5) influenza viruses

To be confirmed

SPI

Lessons learned: how scientific evidence helps policy SPI03

Auditorium 3 - Breakout

NITAGs and Evidence for Influenza Vaccine Recommendations in Middle Income Countries

To be confirmed

12:30 - 14:00

Lunch LUN02

Exhibition hall

12:45 - 13:45

SAT

Satellite Symposium organised by Sanofi: Good, better and best: Shoot the flu with your best shot! SAT06

Auditorium 2 - Breakout

14:00 - 15:30

SCS

Pharmaceutical and non pharmaceutical intervention SCS07

Auditorium 1 - Plenary Hall

Chairs

Peter OPENSHAW

ESWI Board Member, Imperial College

Nisreen OKBA

Icahn School of Medicine at Mount Sinai, United States

Estimated Relative Effectiveness and Public Health Impact of Cell-Based Versus Egg Based Influenza Vaccines During the 2023–2024 Season in the United States

Alicia STEINCSL Seqirus, Australia
Effectiveness of 2024/25 COVID-19 vaccines against symptomatic SARS-CoV-2 infection in the target group for vaccination, European VEBIS primary care multicentre study, autumn/winter 2024/25

To be confirmed
Differential protection of prior infection and repeated vaccination against SARS-CoV-2 infection in Omicron BA.2 to JN.1 predominance: a prospective cohort study

Nicole Ngai Yung TSANGThe University of Hong Kong, Hong Kong SAR China
Vaccine effectiveness against medically attended influenza at primary care level in the paediatric population, 2024/25 season, Europe

Héloïse LUCACCIONIEpiconcept, France
IMMUNOGENICITY AND SAFETY OF HIGH DOSE FORMULATIONS OF MF59-ADJUVANTED CELL-DERIVED INFLUENZA VACCINE IN ADULTS AGED 50 YEARS AND OLDER: TWO PHASE 2 RANDOMISED CONTROLLED TRIALS

Frank ALBANOCSL Seqirus, Australia

SCS

Mathematical modelling and projections, including limitations SCS08

Auditorium 2 - Breakout

Chairs

Colin RUSSELL

ESWI Board Member, Academic Medical Center, University of Amsterdam, Netherlands

Weijia XIONG

The University of Hong Kong, Hong Kong SAR China

A Framework for Measuring Population Immunity Against Influenza Using Individual Antibody Titers

Weijia XIONGThe University of Hong Kong, Hong Kong SAR China
serojump: A Bayesian tool for inferring infection timing and antibody kinetics from longitudinal serological data

David HODGSONLondon School of Hygiene and Tropical Medicine, UK
Integrating Serology and PCR to Infer RSV Infection Dynamics and Correlates of Protection in a Community Cohort in The Gambia

Thushan DE SILVAUniversity of Sheffield, UK
Joint reconstruction of influenza A(H1N1) and A(H3N2) antibody dynamics to estimate the risk of influenza virus infection

Tim TSANGThe University of Hong Kong, Hong Kong SAR China
Investigating the predictive power of machine learning algorithms for antigenic novelty of influenza H3 viruses

Lucy GREENWOODUniversity of Oxford, UK
Comparative Pre-symptomatic Transmission Potential of Influenza A and SARS-CoV-2 in Households

Chengyao ZHANGUniversity of Hong Kong, Hong Kong SAR China

SPI

Implementation of National Immunisation Programmes SPI04

Auditorium 3 - Breakout

Chairs

Ted VAN ESSEN

ESWI Board Member, Netherlands

George KASSIANOS

ESWI Board Member, G Kassianos

Preliminary observation of impact of Maternal RSV Vaccination on Infant Hospitalizations in Mendoza, Argentina: A Comparative Study of the 2023 and 2024 Seasons

Juan Manuel FERNANDEZ MUÑOZMinistry of Health of Mendoza, Argentina
Effectiveness of Maternal Influenza Vaccination in Preventing Influenza Infection in Infants Aged ≤ 6 Months in Korea

To be confirmed

15:30 - 16:00

Coffee Break COF04

Exhibition hall

16:00 - 17:00

SAT

Satellite Symposium organised by CSL Seqirus SAT07

Auditorium 2 - Breakout

17:00 - 18:30

POS

Poster presentations and refreshments POS01

Poster Halls

18:30 - 19:30

ECAS

Early Career Scientists panel discussion - Life after Phd - invitation only ECAS02

External

Wed 22 Oct 2025

08:15 - 09:15

SAT

Satellite Symposium organised by the Global Influenza Initiative through Ogilvy Health: Preventing influenza to safeguard aging populations SAT08

Auditorium 2 - Breakout

09:30 - 10:30

PLE

Keynotes PLE03

Auditorium 1 - Plenary Hall

10:30 - 11:00

Coffee Break COF05

Exhibition hall

11:00 - 12:30

SCS

Future vaccination strategies - PART 2 SCS09

Auditorium 1 - Plenary Hall

Chairs

Florian KRAMMER

ESWI Board Member, Medical University of Vienna, Austria

Marios KOUTSAKOS

University of Melbourne, Australia

A Novel Antigenically Central HA mRNA Vaccine Confers Humoral and Cellular Immune Responses and Protects Ferrets Against Challenge With a Heterologous A(H5) Clade 2.3.4.4b Highly Pathogenic Avian Influenza Virus

Willemijn RIJNINKErasmus MC, Netherlands
Breast milk-derived secretory IgA provides broad protection against influenza A virus

Yona TUGGMcMaster University, Canada
Hemagglutination inhibition antibody titer as correlate of protection against influenza virus infection: a systematic review and meta-analysis

Nancy H. L. LEUNGThe University of Hong Kong, Hong Kong SAR China
Pooled Long-Term Safety Analysis of a Phase 1/2/3 Randomized, Observer-Blind, Controlled Study of the Self-Amplifying mRNA COVID-19 Vaccine ARCT-154 in Adults

To be confirmed
Decades of Evidence Revisited: A Systematic Review on Anti-Neuraminidase Antibody Responses and Influenza-related Outcomes

To be confirmed
Immunogenicity and Reactogenicity of an mRNA-Based Seasonal Influenza and SARS-CoV-2 Multicomponent Vaccine (mRNA-1083) in Adults ≥65 Years With Comorbidities

Lusine KOSTANYANModerna, Inc., United States

SCS

Human challenge studies SCS11

Auditorium 2 - Breakout

Chair

Ab OSTERHAUS

ESWI Board Member, TiHO, Germany

Disease characteristics and immunological profiles obtained from a newly developed hMPV human challenge model

Brandon LONDThVIVO, UK
Evolution of Human Metapneumovirus (HMPV) over the last 20 years and superior isolation of HMPV from clinical samples in organoid-derived bronchial cell cultures to isolation in monolayer cell line cultures

To be confirmed
A Study of the Efficacy, Safety and Immunogenicity of mRNA vaccines in an Influenza B Challenge Model in Healthy Adults

To be confirmed
Development of a Severe Acute Respiratory Syndrome – Coronavirus 2 (SARS-CoV-2) Omicron BA5 human challenge model (HCM) for the assessment of new vaccine and anti-viral therapies in seropositive subjects

Brandon LONDThVIVO, UK

SCS

Clinical Manifestations, burden of disease and management SCS10

Auditorium 3 - Breakout

Chairs

Marco GOEIJENBIER

ESWI Board Member, Spaarne Gasthuis, Netherlands

Valentino D'ONOFRIO

Ghent University, Belgium

Burden of Influenza Hospitalisation (Including With Recent COVID-19) Among Individuals With Immunocompromising Conditions and Other Comorbidities: An Exploratory Analysis Using the INFORM Study Cohort

To be confirmed
Is clinical outcome pathogen related? Characteristics and Outcomes of ICU Patients with Severe Acute Respiratory Infections: Focusing on Respiratory Syncytial Virus, Human Metapneumovirus, Influenza virus, and Parainfluenza virus

Sjoerd VAN DER BIESpaarne Gasthuis, Netherlands
Hospital Burden of Respiratory Syncytial Virus (RSV) in Adults Aged 18 to 60 Years in France: A Nationwide Analysis (2018–2023)

Clarisse DEMONTModerna, France
Clinical outcomes among older adults hospitalized with respiratory syncytial virus and influenza infection – a retrospective study from Israel

To be confirmed
The Effect of Revaccination and Reinfection on Symptom Severity and Prevalence in a Post Covid-19 Condition Cohort

Emma VAN DER SPEKNational Institute for Public Health and the Environment (RIVM), Netherlands
RSV in Patients with Hematological Malignancies: A Multi-centre Retrospective Cohort Study

To be confirmed

12:30 - 14:00

Lunch LUN03

Exhibition hall

12:45 - 13:45

SAT

Satellite Symposium SAT09

Auditorium 2 - Breakout

14:00 - 15:30

SCS

Antiviral and immune therapy SCS12

Auditorium 1 - Plenary Hall

Chairs

Adolfo GARCÍA-SASTRE

Icahn School of Medicine at Mount Sinai, United States

Josefine SCHROEDER

Jena University Hospital, Germany

Effectiveness of the approved antiviral drugs for mild/moderate infection with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in Hong Kong

George OKOLIThe University of Hong Kong, Hong Kong SAR China
Impact of Antiviral Timing and Vaccination on Viral Shedding in Hospitalized Older Adults with COVID-19 During Omicron Predominance

Yun LINWorld Health Organization Collaborating Centre for Infectious Disease Epidemiology and Control, School of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong Special Administrative Region, China, Hong Kong SAR China
Analysis of potential drug combinations against influenza by specifically targeting the viral polymerase

Bahaaeldin ALHAMMADYLeibniz-Institut für Virologie (LIV), Germany
Treatment with pictilisib-loaded lipid nanoparticles reduces influenza A virus infection in vitro and ex vivo

Josefine SCHROEDERJena University Hospital, Germany
Comparative assessment of in vivo antiviral activity of anti-influenza drugs (AD ASTRA)

Podjanee JITTAMALAMahidol University, Thailand

SCS

Virus evolution and strain selection SCS13

Auditorium 2 - Breakout

Chairs

Ron FOUCHIER

Erasmus MC, Netherlands

Kairat TABYNOV

Kazakh National Agrarian Research University, Kazakhstan

High-throughput neutralization measurements correlate strongly with evolutionary success of human influenza strains

Caroline KIKAWAFred Hutch/University of Washington, United States
Antigenic mapping of influenza A viruses using deep learning-based prediction of hemagglutination inhibition titers

Bingyi YANGThe University of Hong Kong, Hong Kong SAR China
Site specific predictability of amino acid substitutions of seasonal influenza viruses

Annelies DE ROOIJAmsterdam University Medical Center, Netherlands
Informal settlements and COVID-19: viral phylodynamic, respiratory microbiome, and public health implications.

Mercedes Soledad NABAES JODARRicardo Gutierrez Children Hospital, Argentina
Linking Poultry Supply Chains and Marketing Practices to the Detection of Novel Genotypes Viruses in Bangladeshi Live Bird Markets

To be confirmed

SPI

Empowering Preparedness: Harnessing Science to Manage Epidemics and Pandemics SPI05

Auditorium 3 - Breakout

Chair

Ed HUTCHINSON

ESWI Board Member, University of Glasgow

Leibniz Lab Pandemic Preparedness: inter- and transdisciplinary approaches towards pandemic resilience in science and society

To be confirmed

15:30 - 16:00

Coffee Break COF06

Exhibition hall

16:00 - 17:30

SCS

Threats from the animal world SCS14 PLE

Auditorium 1 - Plenary Hall

Chairs

Stacey SCHULTZ-CHERRY

St Jude Children's Research Hospital, United States

Kevin CIMINSKI

University Medical Center Freiburg, Germany

Genomic insights into the broadening host range of clade 2.3.4.4b H5 avian influenza viruses

To be confirmed
Emergence of a Novel Reassortant Clade 2.3.2.1e Avian Influenza A/H5N1 Virus Associated with Human Cases in Cambodia

Jurre SIEGERSInstitut Pasteur du Cambodge, Cambodia
Increased attachment to and replication of recent avian H5N1 influenza A viruses from clade 2.3.4.4b in human airway epithelial cells

Lisa BAUERErasmus MC, Netherlands
Bovine Myxovirus Resistance Protein 1 mediates antiviral activity against human and avian influenza A viruses

Rubaiyea FARRUKEEUniversity of Melbourne, Australia

17:30 - 19:00

POS

Poster presentations and refreshments POS02

Poster Halls

Thu 23 Oct 2025

08:15 - 09:15

SAT

Satellite Symposium organised by Pfizer: Unlocking the value of vaccines as a tool to support the management of non-communicable diseases (NCDs) SAT10

Auditorium 1 - Plenary Hall

SAT

Satellite Symposium organised by the ESWI Influenza Diabetes Community and supported by IFPMA SAT11

Auditorium 2 - Breakout

Chair

Tor BIERING-SØRENSEN

University of Copenhagen, Denmark

The Impact of Glycemic Variability on Influenza Outcomes in Intensive Care Patients

Ramon FLUITSpaarne Ziekenhuis: Spaarne Gasthuis, Netherlands

09:30 - 10:30

ECAS

Early Career Scientist Awards and Presentations ECAS03

Auditorium 1 - Plenary Hall

Chairs

Carolien VAN DE SANDT

ESWI Associate Member, The University of Melbourne at the Doherty Institute, Australia

Colin RUSSELL

ESWI Board Member, Academic Medical Center, University of Amsterdam, Netherlands

10:30 - 11:00

Coffee Break COF07

Exhibition hall

11:00 - 12:30

SCS

Late Breakers: novel and outstanding discoveries SCS15

Auditorium 1 - Plenary Hall

Chairs

Sylvie VAN DER WERF

ESWI Associate Member, Institut Pasteur, France

Kirsty SHORT

ESWI Associate Member, University of Queensland, Australia

12:30 - 14:00

Lunch LUN04

Exhibition hall

14:00 - 15:00

SAT

Satellite Symposium organised by the ISOLDA consortium: Improved vaccination Strategies for OLDer Adults (ISOLDA) – a Horizon 2020 project SAT12

Auditorium 1 - Plenary Hall

Chair

Ab OSTERHAUS

ESWI Board Member, TiHO, Germany

The magnitude of mRNA COVID-19 vaccine- induced immune responses in older adults inversely correlate with signs of immunosenescence

Guus RIMMELZWAANUniversity of Veterinary Medicine, Hannover, Germany
Reprogrammed T-cell immunity in COVID-19 mRNA-vaccinated young and older adults

David ESCORS-MURUGARRENNavarrabiomed, Spain
Concomitant administration of COVID-19 mRNA and influenza vaccines: a randomized, single blind, clinical trial to assess immunogenicity in adults aged 65 and over

Bart HAAGMANSErasmus Medical Center, Netherlands

SAT

Satellite Symposium SAT13

Auditorium 2 - Breakout

15:10 - 16:00

PLE

Closing and keynote PLE04

Auditorium 1 - Plenary Hall

Chairs

Colin RUSSELL

ESWI Board Member, Academic Medical Center, University of Amsterdam, Netherlands

Ab OSTERHAUS

ESWI Board Member, TiHO, Germany

Stefania MAGGI

ESWI Board Member, National Research Council of Italy, Italy

Marco GOEIJENBIER

ESWI Board Member, Spaarne Gasthuis, Netherlands

Programme chairs

BIO

Ab OSTERHAUS

ESWI Board Member, TiHO, Germany

BIO

Adolfo GARCÍA-SASTRE

Icahn School of Medicine at Mount Sinai, United States

BIO

Anders MADSEN

Haukeland University Hospital, Norway

BIO

Carolien VAN DE SANDT

ESWI Associate Member, The University of Melbourne at the Doherty Institute, Australia

BIO

Catherine WEIL OLIVIER

independent expert, Trustee of CLCI, France

BIO

Colin RUSSELL

ESWI Board Member, Academic Medical Center, University of Amsterdam, Netherlands

BIO

Corine GEURTS VAN KESSEL

Erasmus MC, Netherlands

BIO

Debby VAN RIEL

ESWI Associate Member, Erasmus MC, Netherlands

BIO

Ed HUTCHINSON

ESWI Board Member, University of Glasgow

BIO

Florian KRAMMER

ESWI Board Member, Medical University of Vienna, Austria

BIO

George KASSIANOS

ESWI Board Member, G Kassianos

BIO

Guus RIMMELZWAAN

University of Veterinary Medicine, Hannover, Germany

BIO

Josefine SCHROEDER

Jena University Hospital, Germany

BIO

Kairat TABYNOV

Kazakh National Agrarian Research University, Kazakhstan

BIO

Kevin CIMINSKI

University Medical Center Freiburg, Germany

BIO

Kevin SELVA

Doherty Institute, University of Melbourne, Australia

BIO

Kirsty SHORT

ESWI Associate Member, University of Queensland, Australia

BIO

Lisa BAUER

Erasmus MC, Netherlands

BIO

Marco DEL RICCIO

University of Florence, Italy

BIO

Marco GOEIJENBIER

ESWI Board Member, Spaarne Gasthuis, Netherlands

BIO

Marios KOUTSAKOS

University of Melbourne, Australia

BIO

Monika REDLBERGER-FRITZ

Medical University Vienna, Austria

BIO

Nisreen OKBA

Icahn School of Medicine at Mount Sinai, United States

BIO

Paula TÄHTINEN

ESWI Board Member, Turku University Hospital and University of Turku, Finland

BIO

Peter OPENSHAW

ESWI Board Member, Imperial College

BIO

Ron FOUCHIER

Erasmus MC, Netherlands

BIO

Stacey SCHULTZ-CHERRY

St Jude Children's Research Hospital, United States

BIO

Stefania MAGGI

ESWI Board Member, National Research Council of Italy, Italy

BIO

Sylvie VAN DER WERF

ESWI Associate Member, Institut Pasteur, France

BIO

Ted VAN ESSEN

ESWI Board Member, Netherlands

BIO

Tor BIERING-SØRENSEN

University of Copenhagen, Denmark

BIO

Valentino D'ONOFRIO

Ghent University, Belgium

BIO

Weijia XIONG

The University of Hong Kong, Hong Kong SAR China

Preliminary programme

Sun 19 Oct 2025
Mon 20 Oct 2025
Tue 21 Oct 2025
Wed 22 Oct 2025
Thu 23 Oct 2025

Programme chairs